Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT)

Historical Holders from Q4 2019 to Q4 2025

Type / Class: Equity / Common Stock, par value $0.0001 per share
Symbol: IMVT on Nasdaq
Shares outstanding: 202,731,676
Price per share: $25.42
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 95,141,975
Total reported value: $1,533,691,024
% of total 13F portfolios: 0.01%
Share change: -1,433,523
Value change: -$22,917,408
Number of holders: 181
Price from insider filings: $25.42

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Roivant Sciences Ltd.	56%	-1.8%	$2,812,776,314	+$413,666,650	113,327,007	+17%	Roivant Sciences Ltd.	12 Dec 2025
FMR LLC	8.4%	-17%	$237,440,423	-$37,858,433	14,729,555	-14%	FMR LLC	30 Sep 2025
Deep Track Capital, LP	5.6%		$139,460,000		9,500,000		Deep Track Capital, LP	19 Mar 2025

As of 30 Sep 2025, Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) has 181 institutional shareholders filing 13F forms. They hold 95,141,975 shares. of 202,731,676 outstanding shares (47%) .

Top 25 institutional shareholders own 41% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
FMR LLC	7.3%	14,729,555	-21%	0.01%	$237,440,423
Deep Track Capital, LP	4.8%	9,728,845	+2.4%	4.4%	$156,828,981
VANGUARD GROUP INC	3.4%	6,826,810	-2.8%	0%	$110,048,178
ARMISTICE CAPITAL, LLC	2.9%	5,836,000	+12%	3%	$94,076,320
BlackRock, Inc.	2.8%	5,738,236	-1.9%	0%	$92,500,364
BAKER BROS. ADVISORS LP	2.7%	5,457,881	0%	0.64%	$87,981,042
T. Rowe Price Investment Management, Inc.	2.5%	5,164,698	-25%	0.05%	$83,255,000
Point72 Asset Management, L.P.	1.7%	3,442,078	+3.2%	0.12%	$55,486,307
STATE STREET CORP	1.4%	2,892,618	+2.2%	0%	$46,629,002
Two Seas Capital LP	1.4%	2,762,040	+23%	2.7%	$44,524,085
Alpine Global Management, LLC	1.4%	2,754,731	+4.9%	11%	$44,406,264
ADAR1 Capital Management, LLC	1.1%	2,241,753	+319%	3.6%	$36,137,058
MORGAN STANLEY	0.97%	1,959,025	-15%	0%	$31,579,490
GEODE CAPITAL MANAGEMENT, LLC	0.89%	1,801,649	-1.3%	0%	$29,047,160
STEMPOINT CAPITAL LP	0.78%	1,589,580	+22%	5.2%	$25,624,030
PERCEPTIVE ADVISORS LLC	0.78%	1,587,890	-26%	0.75%	$25,596,787
Woodline Partners LP	0.74%	1,498,725	0%	0.11%	$24,159,447
GOLDMAN SACHS GROUP INC	0.73%	1,482,539	+24%	0%	$23,898,528
Aberdeen Group plc	0.48%	981,804	+16%	0.03%	$15,826,680
CITADEL ADVISORS LLC	0.37%	746,553	+113%	0.01%	$12,034,434
UBS Group AG	0.36%	726,173	+8.2%	0%	$11,705,908
Prosight Management, LP	0.34%	698,472	+46%	2.7%	$11,259,369
BNP PARIBAS FINANCIAL MARKETS	0.34%	683,402	0%	0.01%	$11,016,440
Pictet Asset Management Holding SA	0.33%	676,577	-43%	0.01%	$10,906,421
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.29%	580,696	-12%	0%	$9,360,820

Institutional Holders of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	251,563	$6,394,359	-$425,595			$25.42	4
2025 Q3	95,141,975	$1,533,691,024	-$22,917,408	$11,345,256	$5,506,254	$16.12	181
2025 Q2	96,236,527	$1,540,423,430	+$25,954,245	$5,656,000	$4,730,540	$16.00	168
2025 Q1	94,088,777	$1,608,317,568	+$221,642,119	$24,846,864	$25,522,081	$17.09	191
2024 Q4	80,137,358	$1,984,993,923	+$2,968,458	$13,881,579	$61,171,204	$24.77	186
2024 Q3	78,641,683	$2,242,992,342	+$115,363,767	$17,976,261	$59,571,338	$28.51	185
2024 Q2	74,722,354	$1,972,582,356	+$111,927,651	$16,597,680	$18,223,680	$26.40	198
2024 Q1	69,647,767	$2,250,302,663	-$5,725,948	$17,634,567	$38,826,727	$32.31	211
2023 Q4	203,049	$8,564,464	+$1,343,341			$42.13	4
2023 Q3	68,143,903	$2,616,088,261	+$460,605,970	$162,992,896	$65,898,552	$38.39	179
2023 Q2	55,460,743	$1,051,890,863	-$33,087,700	$9,528,631	$12,950,819	$18.97	145
2023 Q1	58,264,079	$903,667,804	+$20,897,997	$1,623,897	$7,697,613	$15.51	141
2022 Q4	56,521,696	$1,003,225,649	+$238,927,342	$40,825	$6,033,225	$17.75	131
2022 Q3	42,520,744	$237,252,053	+$14,207,149	$0	$2,053,000	$5.58	105
2022 Q2	39,427,619	$153,779,492	+$1,513,923	$115,000	$1,580,000	$3.90	86
2022 Q1	39,230,681	$216,262,240	+$6,843,816	$399,000	$3,436,000	$5.51	105
2021 Q4	37,686,617	$321,071,547	-$4,301,161	$865,000	$11,110,000	$8.52	117
2021 Q3	33,780,657	$293,597,463	-$49,310,574	$2,799,000	$31,554,000	$8.69	120
2021 Q2	38,525,620	$407,217,405	-$67,542,695	$8,139,000	$33,108,000	$10.57	115
2021 Q1	40,231,074	$645,277,475	-$272,746,357	$6,018,000	$14,572,000	$16.04	117
2020 Q4	40,265,664	$1,859,951,798	+$40,033,560			$46.19	145
2020 Q3	39,826,832	$1,401,558,459	+$384,320,534			$35.19	113
2020 Q2	28,564,750	$695,567,285	+$384,632,450		$0	$24.35	87
2020 Q1	12,628,676	$193,544,419	+$15,204,345		$412,000	$15.56	41
2019 Q4	11,023,832	$170,715,863	+$158,396,016			$15.87	23